Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer

Published:2017-07-03 Issue:6 Volume:26 Page:e12733
ISSN:0961-5423
Container-title:European Journal of Cancer Care
language:en
Short-container-title:Eur J Cancer Care

Author:

Ding H.¹^ORCID,Fang L.¹,Xin W.¹,Tong Y.¹,Zhou Q.²,Huang P.¹

Affiliation:

1. Department of Pharmacy; Zhejiang Cancer Hospital; Hangzhou China

2. Department of Medical Oncology; Zhejiang Cancer Hospital; Hangzhou China

Funder

Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents

“151 Talents Project” in Zhejiang Province

Publisher

Wiley

Subject

Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ecc.12733/fullpdf

Reference21 articles.

1. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada;Beauchemin;Journal of Medical Economics,2016

2. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study;Bonneterre;Journal of Clinical Oncology,2000

3. Bevacizumab in treatment of high-risk ovarian cancer-a cost-effectiveness analysis;Chan;The Oncologist,2014

4. Cancer statistics in China, 2015;Chen;CA,2016

5. Economic evaluation of fulvestrant 500 mg versus generic nonsteroidal aromatase inhibitors in patients with advanced breast cancer in the United Kingdom;Das;Clinical Therapeutics,2013

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Opportunities and prospects for the treatment of hormone-dependent breast cancer;Russian Journal of Oncology;2024-01-11

2. Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review;BMJ Global Health;2023-11

3. Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China;PLOS ONE;2023-02-07

4. Economic evaluation of margetuximab vs. trastuzumab for pretreated ERBB2-positive advanced breast cancer in the US and China;Frontiers in Public Health;2022-09-09

5. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer;Frontiers in Pharmacology;2022-09-09